CASI Pharmaceuticals, Inc. (NASDAQ:CASI) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Friday.

CASI has been the topic of a number of other research reports. Maxim Group reissued a “buy” rating and issued a $4.00 price target on shares of CASI Pharmaceuticals in a research note on Friday, September 8th. HC Wainwright reissued a “buy” rating and issued a $2.00 price target on shares of CASI Pharmaceuticals in a research note on Friday, September 8th.

Shares of CASI Pharmaceuticals (NASDAQ:CASI) traded up 15.38% during trading on Friday, hitting $1.50. 355,943 shares of the company were exchanged. The firm’s market capitalization is $90.29 million. CASI Pharmaceuticals has a 12 month low of $0.91 and a 12 month high of $1.76. The firm’s 50-day moving average price is $1.02 and its 200 day moving average price is $1.12.

CASI Pharmaceuticals (NASDAQ:CASI) last posted its earnings results on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.01). On average, equities research analysts expect that CASI Pharmaceuticals will post ($0.15) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2017/09/15/casi-pharmaceuticals-inc-casi-upgraded-to-hold-by-valuengine.html.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.